在南非优化耐药结核病与HIV新治疗方案结局的移动健康与传统依从性支持干预的自适应评估(ADAP-TIV):一项自适应随机对照试验的研究方案
该研究为前瞻性自适应随机对照试验,在南非夸祖鲁-纳塔尔省纳入同时启动含贝达喹啉的耐多药结核治疗并接受抗逆转录病毒治疗的耐多药结核与HIV成人患者,比较四种依从性支持策略对复合临床结局的效果,主要结局包括12个月时生存、结核培养阴性、保留在 care 及HIV病毒载量检测不到。
要点
- 试验比较增强标准治疗、心理社会支持、移动健康电子剂量监测及两者联合四种依从性支持策略。
- 支持水平依据分化服务交付框架评估治疗支持需求进行滴定。
- 主要复合结局包括12个月时生存、结核培养阴性、保留在 care 及HIV病毒载量检测不到。
核心结论
- 该试验将评估不同依从性支持模式对采用世界卫生组织推荐的全口服耐多药结核方案和抗逆转录病毒治疗的耐多药结核与HIV结局的贡献。
- 该试验还将评估分化服务交付框架用于务实调整耐多药结核与HIV治疗支持水平的效用。
研究设计与样本
- 前瞻性自适应随机对照试验,在南非夸祖鲁-纳塔尔省纳入启动含贝达喹啉的耐多药结核治疗方案并接受抗逆转录病毒治疗的耐多药结核与HIV成人患者。
- 试验组包括增强标准治疗、心理社会支持、使用蜂窝电子剂量监测的移动健康、以及移动健康联合心理社会支持四种依从性支持策略。
- 支持水平依据分化服务交付框架对治疗支持需求的评估进行滴定。
主要发现
- 主要复合结局包括12个月时生存、结核培养阴性、保留在 care 及HIV病毒载量检测不到。
- 次要结局包括主要结局的各个单独组成部分以及依从性对结核和HIV治疗结局的定量评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Highly effective, short-course, bedaquiline-containing treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and integrase strand transfer inhibitor (INSTI)-containing fixed dose combination antiretroviral therapy (ART) have radically transformed treatment for MDR-TB and HIV. However, without advances in adherence support, we may not realize the full potential of these therapeutics. The primary objective of this study is to compare the effect of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform. METHODS: This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of four adherence support strategies on a composite clinical outcome in adults with MDR-TB and HIV initiating bedaquiline-containing MDR-TB treatment regimens and receiving ART in KwaZulu-Natal, South Africa. Trial arms include (1) enhanced standard of care, (2) psychosocial support, (3) mHealth using cellular-enabled electronic dose monitoring, and (4) combined mHealth and psychosocial support. The level of support will be titrated using a differentiated service delivery (DSD)-informed assessment of treatment support needs. The composite primary outcome will include survival, negative TB culture, retention in care, and undetectable HIV viral load at month 12. Secondary outcomes will include individual components of the primary outcome and quantitative evaluation of adherence on TB and HIV treatment outcomes. DISCUSSION: This trial will evaluate the contribution of different modes of adherence support on MDR-TB and HIV outcomes with WHO-recommended all-oral MDR-TB regimens and ART in a high-burden operational setting. We will also assess the utility of a DSD framework to pragmatically adjust levels of MDR-TB and HIV treatment support. TRIAL REGISTRATION: ClinicalTrials.gov NCT05633056. Registered on 1 December 2022.
引用
- Ross J, Perumal R, Wolf A, et al. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials. 2023. PMID: 38037105. doi:10.1186/s13063-023-07520-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。